---
schema_version: "secwatch.filing_event.v1"
accession: "0001323885-24-000060"
form_type: "8-K"
ticker: "ATRC"
cik: "0001323885"
company_name: "AtriCure, Inc."
filed_at: "2024-05-01T23:59:59+00:00"
generated_at: "2026-06-03T02:22:55.693061+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# AtriCure Q1 revenue $108.9M (+16.4% YoY); net loss per share $0.28

## Summary
- Worldwide revenue $108.9M, up 16.4% YoY (16.3% constant currency); U.S. revenue $90.2M (+15.4%), international $18.6M (+21.5%).
- GAAP net loss $0.28 per share vs $0.14 loss in Q1 2023; operating loss $10.9M (includes $4M prior-year legal settlement gain).
- Adjusted EBITDA $2.8M vs $1.9M a year ago; adjusted loss per share $0.25 vs $0.23.
- Gross margin 74.7%, up 21 bps YoY on favorable product/geographic mix.
- CEO cites strong start with growth across all franchises; new product launches and clinical research ahead.

## SEC filing metadata
- accession: 0001323885-24-000060
- form_type: 8-K
- ticker: ATRC
- cik: 0001323885
- company_name: AtriCure, Inc.
- filed_at: 2024-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1323885/000132388524000060/0001323885-24-000060-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1323885/000132388524000060/atrc-20240501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001323885-24-000060
- JSON: https://secwatch.observer/filing/0001323885-24-000060.json
- Plain text: https://secwatch.observer/filing/0001323885-24-000060.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.